Clinical Trials

Thanks to research funded by the PKD Foundation, clinical trials are now exploring several new therapies for PKD. Patients wishing to participate or learn more will find specific information about the therapies below. To participate in a clinical trial, you will need to have a formal diagnosis of PKD. To learn more, click here.

 		 
 
       

 

Tolvaptan binds to the vasopressin receptor on renal cells and blocks cAMP (an intracellular second messenger) formation inside the cell.  Fluid secretion and cell proliferation both reduced resulting in cyst and kidney size.  This drug is not effective in slowing liver cyst formation because liver cells do not have vasopressin receptors.

 

 

Tolvaptan Clinical Trial

 

Tolvaptan Tempo 3 / 4 Trial

 

Intervention:

 Drug - Tolvaptan

Sponsors:

 Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Co., Ltd.

Study Phase:

 III
Status: Active; enrollment complete
Age Group: 18-50

Enrollment goal:

 1,500

Description:

 To evaluate the long-term effectiveness and safety of Tolvaptan by monitoring total kidney volume and cyst volumes by magnetic resonance imaging and measuring a composite of clinical markers in ADPKD patients.
Contact: Within North America: Kristin Cornwell at 866-712-5837 or kristin.cornwell@mayo.edu
Websites: NIH Study Details
 
   
©2009, PKD Foundation  · The PKD Foundation is a 501 (c)(3), 509 (a)(1) public charity.